Lilly Consolidates Evista, Forteo Reps To Address Declining Script Volume
This article was originally published in The Pink Sheet Daily
Executive Summary
A pilot program demonstrated that a "portfolio approach" would more effectively leverage the strength of each product and create synergies between the two, the company says. Evista is experiencing a decline in U.S. prescription volume.